
argenx SE
ARGXHealthcare|Biotechnology|Netherlands
$877.29
-31.87 (-3.50%)
DCF (FCF)
$17.80
Tangible Book
$111.77
Graham Number
$215.25
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
6031.72,
7372.55,
8664.37,
9900.44,
11207.27
],
"ebit_estimate": [
1903.74,
2465.21,
3262,
4041.97,
5055.31
],
"ebitda_estimate": [
1941.51,
2413.67,
3221.45,
4221.74,
4855
],
"net_income_estimate": [
1776.34,
2375.13,
3013.89,
3503.33,
4341.22
],
"per_share_eps_estimate": [
26.87,
34.71,
45.58,
49.61,
60.24
],
"eps_nri_estimate": [
26.22,
35.6,
43.31,
50.13,
64.67
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
146.95,
183.42,
240.47,
330.85,
416.09
],
"pretax_income_estimate": [
2057.1,
2762.48,
3519.49,
4250.73,
5325.57
],
"operating_cash_flow_per_share_estimate": [
30.15,
36.99,
47.06,
70.76,
79.56
],
"roa_estimate": [
19.48,
20.58,
18.5,
18.9,
18.7
],
"roe_estimate": [
22.64,
22.86,
20.91,
20.53,
19.77
],
"gross_margin_estimate": [
89.53,
89.46,
88.52,
90.4,
90.4
],
"operating_cash_flow_estimate": [
2000.66,
2454.43,
3122.93,
4695.09,
5279.03
],
"pettm_estimate": [
32.65,
25.28,
19.25,
17.68,
14.56
],
"long_term_growth_rate_mean": 32.84,
"long_term_revenue_growth_rate_mean": "26.85",
"future_per_share_eps_estimate_growth": 33.65,
"future_eps_nri_estimate_growth": 32.84,
"future_revenue_estimate_growth": 26.85,
"future_ebit_estimate_growth": 46.22,
"future_ebitda_estimate_growth": 45.47,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 34.41,
"future_pretax_income_estimate_growth": 42.21,
"future_book_value_per_share_estimate_growth": 27.72,
"future_roa_estimate_growth": 2.19,
"future_roe_estimate_growth": 3.97,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 63.39
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
1442.69,
1567.11,
1692.72,
1712.47,
1815.05,
1883.01,
1973.74,
1964.11
],
"ebit_estimate": [
435.14,
502.85,
540.8,
567.13,
637.68,
696.14,
790.41,
null
],
"ebitda_estimate": [
434.72,
500.27,
509.1,
null,
null,
null,
null,
null
],
"net_income_estimate": [
409.97,
462.52,
498.81,
500.61,
574.67,
624.57,
706.37,
null
],
"per_share_eps_estimate": [
6.19,
7.02,
7.54,
7.74,
8.7,
9.28,
10.23,
null
],
"eps_nri_estimate": [
6.15,
6.87,
7.49,
7.45,
8.38,
8.86,
9.81,
11.64
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
91.89,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
478,
539.92,
578.34,
596.9,
684.45,
743.24,
838.51,
null
],
"operating_cash_flow_per_share_estimate": [
6.09,
7.14,
6.41,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
50.4,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
89.47,
89.47,
88.96,
91,
91,
91,
89,
null
],
"operating_cash_flow_estimate": [
404.11,
473.79,
425.35,
null,
null,
null,
null,
null
],
"pettm_estimate": [
30.8,
28.31,
26.38,
24.4,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 32.84,
"long_term_revenue_growth_rate_mean": "26.85",
"future_per_share_eps_estimate_growth": 33.65,
"future_eps_nri_estimate_growth": 32.84,
"future_revenue_estimate_growth": 26.85,
"future_ebit_estimate_growth": 46.22,
"future_ebitda_estimate_growth": 45.47,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 34.41,
"future_pretax_income_estimate_growth": 42.21,
"future_book_value_per_share_estimate_growth": 27.72,
"future_roa_estimate_growth": 2.19,
"future_roe_estimate_growth": 3.97,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 63.39
}